Rhabdoid tumor
MONDO:0002728An aggressive malignant embryonal neoplasm usually occurring during childhood. It is characterized by the presence of large cells with abundant cytoplasm, large eccentric nucleus, and a prominent nucleolus and it is associated with abnormalities of chromosome 22. It can arise from the central nervous system, kidney, and the soft tissues. The prognosis is poor.
Also known as: malignant rhabdoid tumor, rhabdoid sarcoma, rhabdoid tumor, rhabdoid cancer
2894 clinical trials for this condition and its sub-types, 63 tagged with Rhabdoid tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Rhabdoid tumor
-
Atypical teratoid rhabdoid tumor 35 trials · 36 incl. sub-types
1 sub-type
-
Rhabdoid tumor of the kidney 7 trials
-
Extrarenal rhabdoid tumor 1 trial
-
Familial rhabdoid tumor 0 trials · 1 incl. sub-types
2 sub-types
-
Striated muscle rhabdoid tumor 0 trials
-
New drug cocktail targets rare, aggressive kidney cancer
Disease control CompletedThis phase II trial is testing whether combining the targeted drug ixazomib with two chemotherapy drugs (gemcitabine and doxorubicin) can shrink tumors or stop them from growing in patients with a rare and aggressive kidney cancer called renal medullary carcinoma. The study enrol…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for kids with resistant cancers? drug combo shows promise in early trial
Disease control CompletedThis study tested the safety and effectiveness of the drug abemaciclib combined with other cancer medicines in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if th…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New stem cell transplant shows promise for kids with tough cancers
Disease control CompletedThis study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immune cells injected directly into brain show promise for kids with tough tumors
Disease control CompletedThis early-stage study tested a new treatment for children and young adults with brain tumors that came back or didn't respond to standard therapy. Doctors took the patients' own immune cells, modified them to recognize a protein called EGFR on tumor cells, and injected them dire…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Large study digs into rare brain tumors to uncover clues
Knowledge-focused CompletedThis study gathered information from 326 adults with rare central nervous system tumors, such as medulloblastoma and ependymoma. Participants completed surveys about their symptoms, treatments, and lifestyle, and provided a saliva sample for genetic analysis. The goal was to lear…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Protein map of rare childhood cancer could reveal new attack points
Knowledge-focused CompletedThis study looked at protein patterns in tumor samples from 44 children with a rare cancer called rhabdoid tumor. Researchers used advanced techniques to see how tumors differ from each other. The goal was to find new targets for future treatments. The study is complete and did n…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Scientists map hidden diversity in rare childhood tumors
Knowledge-focused CompletedThis study looked at tumor samples from 15 children with rhabdoid tumors to understand why some parts of the tumor resist treatment. By analyzing individual cells, researchers aimed to identify different cell types within each tumor and find potential new targets for therapy. The…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Can a Child's tumor DNA guide better cancer treatment?
Knowledge-focused CompletedThis study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…
Sponsor: Giselle Sholler • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC